XTL Biopharmaceuticals (XTLB) said it reached an agreement for the use and supply of CyDex Pharmaceuticals's Captisol in the formulation of XTL's lead drug, hCDR1, for the treatment of systemic lupus erythematosus. Under the deal, XTL will receive a non-exclusive, royalty-free license to use Captisol in the formulation of its drug for the purpose of conducting its advanced clinical study on hCDR1 for the treatment of SLE, subject to the payment of certain milestone and other payments.